Ebola Virus Disease Vaccine Efforts Gain Momentum as Russia Reports Progress, Oxford-Serum Trial Planned in Three Months

Summary:
The worsening Ebola outbreak in the Democratic Republic of the Congo has triggered global concern after the World Health Organization declared it a public health emergency of international concern. While no approved vaccine currently exists for the Bundibugyo strain, Russia has claimed progress in developing a vaccine that may offer protection against the variant. At the same time, researchers from the University of Oxford and the Serum Institute of India are accelerating vaccine development using the ChAdOx platform, with clinical-grade doses potentially ready within two to three months. Health agencies worldwide are now intensifying vaccine production, regulatory coordination, and outbreak response efforts as the virus continues spreading across Congo, Uganda, and South Sudan. 

The rapidly escalating Ebola outbreak in the Democratic Republic of the Congo has drawn global concern after the World Health Organization classified the situation as a “public health emergency of international concern.” At present, no officially approved vaccines or treatments are available specifically for the Bundibugyo strain responsible for the outbreak.

Amid the crisis, the Russian Embassy in South Africa announced that Russian researchers have developed a vaccine targeting a new Ebola variant. The announcement was reportedly made by Russian Health Minister Mikhail Murashko. In a statement shared on X, the embassy said Russian scientists had successfully created a vaccine against the emerging Ebola strain.

The embassy further noted that the vaccine could potentially provide protection against the rare Bundibugyo strain associated with the current outbreak in the Democratic Republic of the Congo, offering a possible breakthrough in ongoing containment efforts.

At the same time, researchers from the University of Oxford, working in collaboration with global partners including the Serum Institute of India, are accelerating the development of vaccines and therapies for the Ebola strain affecting Congo, Uganda, and South Sudan.

Scientists at Oxford stated that early-stage vaccine development is progressing quickly, and clinical-grade doses could become available within two to three months if ongoing pre-clinical studies continue successfully.

Professor Teresa Lambe, Head of Vaccine Immunology at Oxford’s Pandemic Sciences Institute, said animal studies for the vaccine candidate are already underway in partnership with organisations worldwide. She added that the Serum Institute’s ability to scale manufacturing rapidly could help deliver clinical-grade vaccine doses within the projected timeline.

According to Oxford researchers, the vaccine candidate is based on the ChAdOx platform — the same adenoviral vector technology used in Oxford’s COVID-19 vaccine programme. Scientists explained that leveraging this existing platform has accelerated development because extensive safety and immune-response data are already available from previous research.

Professor Lambe noted that the platform enables faster progress in both early testing and manufacturing readiness. The vaccine is currently being designed as a single-dose candidate, similar to the licensed Ebola Zaire vaccine, with researchers aiming to generate strong antibody and T-cell immune responses considered essential for protection against the virus.

However, scientists cautioned that the durability of immunity against the Bundibugyo Ebola strain is still not fully understood and requires further research.

The current Ebola outbreak, caused by the Bundibugyo Ebolavirus strain, has spread across parts of central and eastern Africa, including Congo, Uganda, and South Sudan.

Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, stated that the outbreak is currently advancing faster than response measures, with suspected deaths increasing sharply in recent weeks. The worsening situation has prompted urgent international coordination involving vaccine developers, manufacturing partners, the Coalition for Epidemic Preparedness Innovations, Oxford’s biomanufacturing facilities, and accelerated regulatory approvals in affected nations.

Global health agencies and researchers are now focusing on rapidly expanding vaccine production and strengthening emergency response measures to help contain the outbreak.